Emergent BioSolutions Inc. announced it has secured approximately $400 million in orders for 2024 and 2025 related to its vaccinia, smallpox, and mpox product portfolio. This includes the U.S. government contract modification for ACAM2000 and exercised CNJ-016 (VIGIV) contract options from 2023 and 2024.
To date in 2024, customer orders totaling nearly $210 million for ACAM2000 and VIGIV have been delivered. An additional $185+ million in ACAM2000 and VIGIV orders are confirmed for delivery in the remainder of 2024 and into 2025.
The U.S. Food and Drug Administration approved an update for ACAM2000 in August to include prevention of mpox disease in high-risk individuals. Emergent also submitted an Expression of Interest for ACAM2000 vaccine to the World Health Organization for Emergency Use Listing evaluation and donated 50,000 doses for deployment across Africa.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.